Profile of darunavir in the management of treatment-experienced HIV patients

Profile of darunavir in the management of treatment-experienced HIV patients

Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cameron Wolfe, Charles Hicks
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/f8f886a94fd04aa68ae968125536033c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f8f886a94fd04aa68ae968125536033c
record_format dspace
spelling oai:doaj.org-article:f8f886a94fd04aa68ae968125536033c2021-12-02T05:11:20ZProfile of darunavir in the management of treatment-experienced HIV patients1179-1373https://doaj.org/article/f8f886a94fd04aa68ae968125536033c2009-09-01T00:00:00Zhttp://www.dovepress.com/profile-of-darunavir-in-the-management-of-treatment-experienced-hiv-pa-a3582https://doaj.org/toc/1179-1373Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.Keywords: darunavir, HIV, ritonavir Cameron WolfeCharles HicksDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2009, Iss Default, Pp 13-21 (2009)
institution DOAJ
collection DOAJ
language EN
topic Immunologic diseases. Allergy
RC581-607
spellingShingle Immunologic diseases. Allergy
RC581-607
Cameron Wolfe
Charles Hicks
Profile of darunavir in the management of treatment-experienced HIV patients
description Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.Keywords: darunavir, HIV, ritonavir
format article
author Cameron Wolfe
Charles Hicks
author_facet Cameron Wolfe
Charles Hicks
author_sort Cameron Wolfe
title Profile of darunavir in the management of treatment-experienced HIV patients
title_short Profile of darunavir in the management of treatment-experienced HIV patients
title_full Profile of darunavir in the management of treatment-experienced HIV patients
title_fullStr Profile of darunavir in the management of treatment-experienced HIV patients
title_full_unstemmed Profile of darunavir in the management of treatment-experienced HIV patients
title_sort profile of darunavir in the management of treatment-experienced hiv patients
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/f8f886a94fd04aa68ae968125536033c
work_keys_str_mv AT cameronwolfe profileofdarunavirinthemanagementoftreatmentexperiencedhivpatients
AT charleshicks profileofdarunavirinthemanagementoftreatmentexperiencedhivpatients
_version_ 1718400569833422848

Ejemplares similares